Apr 6 2010
PinPointe USA, Inc., a privately held emerging medical device company developing advanced laser-based technology and products for the treatment of onychomycosis (toenail fungus) today announced that it has certified its first PinPointe FootLaser Provider in Australia to administer its revolutionary new treatment for toenail fungus.
The Certified Provider, Paul W. Bours, Podiatric Surgeon, is currently offering the PinPointe FootLaser treatment at the Institute of Surgical Podiatry in Sydney, Australia. The PinPointe FootLaser received approval last year from the Therapeutic Goods Administration (TGA), certifying it has met the TGA’s consumer and health safety standards and can be offered by certified health care providers throughout Australia.
The PinPointe FootLaser uses patented and patent-pending laser technology designed to target the pathogens that cause toenail fungus, an infection that afflicts an estimated 900 million people. The PinPointe FootLaser was introduced to Europe in the United Kingdom in May 2009 after receiving CE Mark approval. Since then, it has continued to expand its reach in Europe, with certified providers in the United Kingdom, Germany and Turkey administering this revolutionary new laser treatment for toenail fungus. In the United States, the PinPointe FootLaser is cleared for general use in dermatology and podiatry, but is not yet cleared for the treatment of onychomycosis.
With the PinPointe FootLaser, patients are treated quickly and effectively with no oral or systemic drugs and no anesthesia. The procedure is completely non-invasive and allows the new nail to grow in healthy and clear. Unlike medication-driven treatments for toenail fungus, the PinPointe FootLaser presents minimal risk of side effects. Systemic medications can result in a wide variety of side effects, including liver toxicity. A pilot study evaluating the PinPointe FootLaser demonstrated a significant percentage of the patients studied had clear nail growth after treatment.
Paul W. Bours, Podiatric Surgeon noted: “For many of my patients, toenail fungus is an ongoing and nagging problem. Not only is it an uncomfortable condition, but many people feel stigmatized by it. When I first heard about the PinPointe FootLaser I was thrilled that I would finally have an alternative treatment that would provide effective and pain-free relief. By administering this treatment, I am looking forward to helping many patients improve their quality of life.”
Noted Bob H. Katz, CEO of PinPointe USA: “The PinPointe FootLaser has been a great benefit for many sufferers of toenail fungus in Europe, and we’re very pleased to now enter the Australian market with our innovative treatment, and with a premier healthcare professional like Dr. Bours. We look forward to quickly offering this valuable foot care service in additional cities throughout Australia and New Zealand in the coming months.”